In our quest to provide solutions to community urologist practices, UroGPO has maintained a strong focus on advanced prostate cancer, and we are very proud of the mRCPC Clinical Guideline created by the UroGPO Medical Advisory Group in September 2014. When we asked the membership, “What’s next?” the definitive answer was overactive bladder (OAB).

In listening to our membership, UroGPO is finalizing details on forming our OAB Medical Advisory Group to convene in late August. The goal of the meeting will be to make sense of the treatment pattern in practice around OAB patients.

OAB creates more of an operational challenge. The sequencing of products seems to be more straightforward than mCRPC. The challenge with OAB patients is keeping them engaged with the urologist. OAB patients will fill their prescriptions at the retail pharmacy and then either have success with that therapy, or fail and fall of the urologists radar screen. The ultimate goal will be to keep that patient connected to the practice after first line therapy failure.

At the American Urological Association (AUA) meeting in New Orleans, Dr. Sandy Siegel initiated an impromptu conversation with representatives from Medtronic and Allergan, both of which play a significant role in the OAB treatment protocol. Medtronic and Allergan have shown a willingness to evaluate the UroGPO process with our Medical Advisory Group and have offered helpful direction in organizing the OAB space. Astellas is also involved and interested in participating. Thank you, Dr. Siegel, for your efforts.

Moving forward, UroGPO will continue to focus on patient identification and gaps in care, as well as the proper treatment for individual patients. This project is meant to assist UroGPO members in keeping their patients in their practice for a greater period of time, as we have done with the prostate cancer patient. We look forward to your feedback.